Top-Rated StocksTop-RatedNASDAQ:MIRM Mirum Pharmaceuticals (MIRM) Stock Price, News & Analysis → The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad) Free MIRM Stock Alerts $23.85 -0.16 (-0.67%) (As of 04/17/2024 ET) Add Compare Share Share Today's Range$23.80▼$24.6350-Day Range$23.85▼$29.9352-Week Range$23.76▼$35.56Volume327,435 shsAverage Volume572,455 shsMarket Capitalization$1.12 billionP/E RatioN/ADividend YieldN/APrice Target$52.11 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Mirum Pharmaceuticals alerts: Email Address Mirum Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.13 Rating ScoreUpside/Downside116.8% Upside$51.70 Price TargetShort InterestBearish17.36% of Shares Sold ShortDividend StrengthN/ASustainability-1.69Upright™ Environmental ScoreNews Sentiment0.04Based on 8 Articles This WeekInsider TradingSelling Shares$130,267 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.12) to $1.08 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.28 out of 5 starsMedical Sector220th out of 913 stocksBiotechnology Industry10th out of 65 stocks 4.6 Analyst's Opinion Consensus RatingMirum Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMirum Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 0.0 Short Interest Percentage of Shares Shorted17.36% of the outstanding shares of Mirum Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverMirum Pharmaceuticals has a short interest ratio ("days to cover") of 13.9, which indicates bearish sentiment.Change versus previous monthShort interest in Mirum Pharmaceuticals has recently increased by 0.25%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldMirum Pharmaceuticals does not currently pay a dividend.Dividend GrowthMirum Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMirum Pharmaceuticals has received a 61.01% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Liver-disease medication (A05)", "Clinical research services for physiological diseases ", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Mirum Pharmaceuticals is -1.69. Previous Next 2.2 News and Social Media Coverage News SentimentMirum Pharmaceuticals has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.35 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Mirum Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 3 people have searched for MIRM on MarketBeat in the last 30 days. This is a decrease of -73% compared to the previous 30 days.MarketBeat Follows3 people have added Mirum Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mirum Pharmaceuticals insiders have sold 28.72% more of their company's stock than they have bought. Specifically, they have bought $101,200.00 in company stock and sold $130,267.00 in company stock.Percentage Held by Insiders24.06% of the stock of Mirum Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Mirum Pharmaceuticals are expected to grow in the coming year, from ($1.12) to $1.08 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mirum Pharmaceuticals is -6.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mirum Pharmaceuticals is -6.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMirum Pharmaceuticals has a P/B Ratio of 4.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeThe “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! About Mirum Pharmaceuticals Stock (NASDAQ:MIRM)Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.Read More MIRM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MIRM Stock News HeadlinesMarch 28, 2024 | insidertrades.comEric Bjerkholt Purchases 2,000 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) StockMarch 26, 2024 | insidertrades.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Sells $111,017.40 in StockApril 18, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.March 19, 2024 | insidertrades.comEric Bjerkholt Buys 2,000 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) StockApril 17, 2024 | msn.comStifel Initiates Coverage of Mirum Pharmaceuticals (MIRM) with Buy RecommendationApril 17, 2024 | markets.businessinsider.comBuy Rating Affirmed for Mirum Pharmaceuticals Amidst Strategic Positioning and Treatment BreakthroughsApril 17, 2024 | americanbankingnews.comMirum Pharmaceuticals (NASDAQ:MIRM) Reaches New 1-Year Low at $24.17April 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Mirum Pharmaceuticals Amid Positive Clinical Trial OutlookApril 18, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.April 10, 2024 | businesswire.comMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 9, 2024 | americanbankingnews.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Consensus Rating of "Buy" from AnalystsApril 2, 2024 | finance.yahoo.comMirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille SyndromeApril 2, 2024 | businesswire.comMirum Pharmaceuticals' LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada's CADTH for Patients with Cholestatic Pruritus in Alagille SyndromeMarch 26, 2024 | finance.yahoo.comMirum Pharmaceuticals Inc (MIRM) Insider Sells SharesMarch 20, 2024 | investing.comMirum Pharmaceuticals COO sells over $28k in company stockMarch 18, 2024 | markets.businessinsider.comCracking The Code: Understanding Analyst Reviews For Mirum PharmaceuticalsMarch 15, 2024 | ca.finance.yahoo.comMIRM Mar 2024 40.000 callMarch 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Mirum Pharmaceuticals Following FDA Approval and Promising Pipeline DevelopmentsMarch 14, 2024 | msn.comFDA Approves Mirum's Livmarli For Liver Disease In Kids As Young As 5 Years: Analyst Bullish On Label Expansion StrategyMarch 14, 2024 | marketwatch.comMirum Pharmaceuticals Gets Additional FDA Approval for LivmarliMarch 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Mirum Pharmaceuticals Following FDA Approval and Positive Revenue OutlookMarch 14, 2024 | msn.com3 Best Stocks to Buy Now, 3/14/2024, According to Top AnalystsMarch 14, 2024 | msn.comMirum gains as FDA accepts label expansion of liver disease drugMarch 13, 2024 | reuters.comUS FDA approves expanded use of Mirum's liver disease drugMarch 13, 2024 | finance.yahoo.comMirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic CholestasisMarch 13, 2024 | businesswire.comMirum Pharmaceuticals' LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic CholestasisMarch 8, 2024 | businesswire.comMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)See More Headlines Receive MIRM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mirum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today4/17/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:MIRM CUSIPN/A CIK1759425 Webmirumpharma.com Phone(650) 667-4085FaxN/AEmployees264Year FoundedN/APrice Target and Rating Average Stock Price Target$51.70 High Stock Price Target$72.00 Low Stock Price Target$35.00 Potential Upside/Downside+118.5%Consensus RatingBuy Rating Score (0-4)3.13 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($3.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-163,410,000.00 Net Margins-86.33% Pretax Margin-87.15% Return on Equity-66.24% Return on Assets-23.55% Debt Debt-to-Equity Ratio1.23 Current Ratio4.45 Quick Ratio4.19 Sales & Book Value Annual Sales$186.37 million Price / Sales6.01 Cash FlowN/A Price / Cash FlowN/A Book Value$5.33 per share Price / Book4.47Miscellaneous Outstanding Shares47,003,000Free Float35,694,000Market Cap$1.12 billion OptionableOptionable Beta1.14 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Christopher Peetz (Age 45)CEO & Director Comp: $1.09MMr. Peter Radovich M.B.A. (Age 46)Ph.D., COO & President Comp: $732.15kDr. Pamela Vig Ph.D. (Age 53)Chief Scientific Officer & Head of Research Comp: $678.2kMs. Lara Longpre MBA (Age 54)MSC, Chief Development Officer Comp: $678.2kMr. Eric H. Bjerkholt M.B.A. (Age 64)Chief Financial Officer Andrew McKibbenVice President of Investor Relations and FinanceMr. Paul K. RossChief Compliance OfficerMs. Erin Campany (Age 56)Senior Vice President of Human Resources Dr. Ian Clements Ph.D. (Age 55)Consultant Comp: $649.1kMs. Vinita P. KumarSenior vice President of QualityMore ExecutivesKey CompetitorsProthenaNASDAQ:PRTACentessa PharmaceuticalsNASDAQ:CNTAXencorNASDAQ:XNCROcular TherapeutixNASDAQ:OCULCollegium PharmaceuticalNASDAQ:COLLView All CompetitorsInsiders & InstitutionsHennion & Walsh Asset Management Inc.Bought 15,022 shares on 4/17/2024Ownership: 0.135%Wealth Enhancement Advisory Services LLCSold 862 shares on 4/16/2024Ownership: 0.067%Los Angeles Capital Management LLCBought 4,069 shares on 4/5/2024Ownership: 0.089%Eric BjerkholtBought 2,000 shares on 3/27/2024Total: $49,600.00 ($24.80/share)Peter RadovichSold 4,303 sharesTotal: $111,017.40 ($25.80/share)View All Insider TransactionsView All Institutional Transactions MIRM Stock Analysis - Frequently Asked Questions Should I buy or sell Mirum Pharmaceuticals stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mirum Pharmaceuticals in the last twelve months. There are currently 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MIRM shares. View MIRM analyst ratings or view top-rated stocks. What is Mirum Pharmaceuticals' stock price target for 2024? 9 Wall Street analysts have issued twelve-month price targets for Mirum Pharmaceuticals' stock. Their MIRM share price targets range from $35.00 to $72.00. On average, they anticipate the company's share price to reach $51.70 in the next twelve months. This suggests a possible upside of 116.8% from the stock's current price. View analysts price targets for MIRM or view top-rated stocks among Wall Street analysts. How have MIRM shares performed in 2024? Mirum Pharmaceuticals' stock was trading at $29.52 at the beginning of the year. Since then, MIRM stock has decreased by 19.2% and is now trading at $23.85. View the best growth stocks for 2024 here. When is Mirum Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our MIRM earnings forecast. How were Mirum Pharmaceuticals' earnings last quarter? Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) posted its quarterly earnings data on Wednesday, February, 28th. The company reported ($0.66) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by $0.32. The company earned $69.55 million during the quarter, compared to analyst estimates of $66.73 million. Mirum Pharmaceuticals had a negative net margin of 86.33% and a negative trailing twelve-month return on equity of 66.24%. What ETFs hold Mirum Pharmaceuticals' stock? ETFs with the largest weight of Mirum Pharmaceuticals (NASDAQ:MIRM) stock in their portfolio include Simplify Propel Opportunities ETF (SURI).Virtus LifeSci Biotech Products ETF (BBP). What other stocks do shareholders of Mirum Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mirum Pharmaceuticals investors own include Pfizer (PFE), Fulcrum Therapeutics (FULC), OPKO Health (OPK), Vaxart (VXRT), Advanced Micro Devices (AMD), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), Trevena (TRVN), VBI Vaccines (VBIV) and Dynavax Technologies (DVAX). When did Mirum Pharmaceuticals IPO? Mirum Pharmaceuticals (MIRM) raised $75 million in an IPO on Thursday, July 18th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Evercore ISI and Guggenheim Securities acted as the underwriters for the IPO and Raymond James and Roth Capital Partners were co-managers. Who are Mirum Pharmaceuticals' major shareholders? Mirum Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.14%), Los Angeles Capital Management LLC (0.09%) and Wealth Enhancement Advisory Services LLC (0.07%). Insiders that own company stock include Christopher Peetz, Eric Bjerkholt, Ian Clements, James E Flynn, John A Maurer, Jolanda Howe, Lara Longpre, Michael G Grey, Niall O'donnell, Pamela Vig, Patrick J Heron and Peter Radovich. View institutional ownership trends. How do I buy shares of Mirum Pharmaceuticals? Shares of MIRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MIRM) was last updated on 4/18/2024 by MarketBeat.com Staff From Our Partners[Urgent!] Generational Wealth GameplanCrypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsUrgent alert: open this for a huge profit potentialTimothy SykesTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market AlertsBiden out June 13; Kamala won’t replace him?Paradigm PressThe #1 Crypto for 2024InvestorPlaceOptions trading has suddenly become more reliable.Eagle Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mirum Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.